BACKGROUND: Factors associated with initiation of sexual activity among perinatally human immunodeficiency virus (HIV)-infected (PHIV(+)) youth, and the attendant potential for sexual transmission of antiretroviral (ARV) drug-resistant HIV, remain poorly understood. METHODS: We conducted cross-sectional and longitudinal analyses of PHIV(+) youth aged 10-18 years (mean, 13.5 years) enrolled in the US-based Pediatric HIV/AIDS Cohort Study between 2007 and 2009. Audio computer-assisted self-interviews (ACASI) were used to collect sexual behavior information. RESULTS: Twenty-eight percent (95% confidence interval [CI], 23%-33%) (92/330) of PHIV(+) youth reported sexual intercourse (SI) (median initiation age, 14 years). Sixty-two percent (57/92) of sexually active youth reported unprotected SI. Among youth who did not report history of SI at baseline, ARV nonadherence was associated with sexual initiation during follow-up (adjusted hazard ratio, 2.87; 95% CI, 1.32-6.25). Youth living with a relative other than their biological mother had higher odds of engaging in unprotected SI than those living with a nonrelative. Thirty-three percent of youth disclosed their HIV status to their first sexual partner. Thirty-nine of 92 (42%) sexually active youth had HIV RNA ≥5000 copies/mL after sexual initiation. Viral drug resistance testing, available for 37 of these 39 youth, identified resistance to nucleoside reverse transcriptase inhibitors in 62%, nonnucleoside reverse transcriptase inhibitors in 57%, protease inhibitors in 38%, and all 3 ARV classes in 22%. CONCLUSIONS: As PHIV(+) youth become sexually active, many engage in behaviors that place their partners at risk for HIV infection, including infection with drug-resistant virus. Effective interventions to facilitate youth adherence, safe sex practices, and disclosure are urgently needed.
BACKGROUND: Factors associated with initiation of sexual activity among perinatally human immunodeficiency virus (HIV)-infected (PHIV(+)) youth, and the attendant potential for sexual transmission of antiretroviral (ARV) drug-resistant HIV, remain poorly understood. METHODS: We conducted cross-sectional and longitudinal analyses of PHIV(+) youth aged 10-18 years (mean, 13.5 years) enrolled in the US-based Pediatric HIV/AIDS Cohort Study between 2007 and 2009. Audio computer-assisted self-interviews (ACASI) were used to collect sexual behavior information. RESULTS: Twenty-eight percent (95% confidence interval [CI], 23%-33%) (92/330) of PHIV(+) youth reported sexual intercourse (SI) (median initiation age, 14 years). Sixty-two percent (57/92) of sexually active youth reported unprotected SI. Among youth who did not report history of SI at baseline, ARV nonadherence was associated with sexual initiation during follow-up (adjusted hazard ratio, 2.87; 95% CI, 1.32-6.25). Youth living with a relative other than their biological mother had higher odds of engaging in unprotected SI than those living with a nonrelative. Thirty-three percent of youth disclosed their HIV status to their first sexual partner. Thirty-nine of 92 (42%) sexually active youth had HIV RNA ≥5000 copies/mL after sexual initiation. Viral drug resistance testing, available for 37 of these 39 youth, identified resistance to nucleoside reverse transcriptase inhibitors in 62%, nonnucleoside reverse transcriptase inhibitors in 57%, protease inhibitors in 38%, and all 3 ARV classes in 22%. CONCLUSIONS: As PHIV(+) youth become sexually active, many engage in behaviors that place their partners at risk for HIV infection, including infection with drug-resistant virus. Effective interventions to facilitate youth adherence, safe sex practices, and disclosure are urgently needed.
Authors: M J Rotheram-Borus; M B Lee; D A Murphy; D Futterman; N Duan; J M Birnbaum; M Lightfoot Journal: Am J Public Health Date: 2001-03 Impact factor: 9.308
Authors: Robert H Remien; Theresa M Exner; Stephen F Morin; Anke A Ehrhardt; Mallory O Johnson; Jackie Correale; Stephanie Marhefka; Sheri B Kirshenbaum; Lance S Weinhardt; Mary Jane Rotheram-Borus; Sheryl L Catz; Cheryl Gore-Felton; Margaret A Chesney; Jeffrey Kelly Journal: AIDS Behav Date: 2007-01-23
Authors: Miguel de Mulder; Gonzalo Yebra; Leticia Martín; Luís Prieto; María José Mellado; Pablo Rojo; María Ángeles Muñoz-Fernández; Santiago Jiménez de Ory; José Tomas Ramos; Africa Holguín Journal: J Antimicrob Chemother Date: 2011-08-02 Impact factor: 5.790
Authors: Tracey E Wilson; Yolanda Barrón; Mardge Cohen; Jean Richardson; Ruth Greenblatt; Henry S Sacks; Mary Young Journal: Clin Infect Dis Date: 2002-01-09 Impact factor: 9.079
Authors: Pierre-André Michaud; Joan-Carles Suris; L Ralph Thomas; Christian Kahlert; Christoph Rudin; Jean-Jacques Cheseaux Journal: J Adolesc Health Date: 2008-10-29 Impact factor: 5.012
Authors: Gayatri Mirani; Paige L Williams; Miriam Chernoff; Mark J Abzug; Myron J Levin; George R Seage; James M Oleske; Murli U Purswani; Rohan Hazra; Shirley Traite; Bonnie Zimmer; Russell B Van Dyke Journal: Clin Infect Dis Date: 2015-08-12 Impact factor: 9.079
Authors: Amelia Bucek; Claude Ann Mellins; Cheng-Shiun Leu; Curtis Dolezal; Rehema Korich; Andrew Wiznia; Elaine J Abrams Journal: AIDS Care Date: 2019-09-19
Authors: Anne M Neilan; Brad Karalius; Kunjal Patel; Russell B Van Dyke; Mark J Abzug; Allison L Agwu; Paige L Williams; Murli Purswani; Deborah Kacanek; James M Oleske; Sandra K Burchett; Andrew Wiznia; Miriam Chernoff; George R Seage; Andrea L Ciaranello Journal: JAMA Pediatr Date: 2017-05-01 Impact factor: 16.193
Authors: Lynnette L Harris; Miriam C Chernoff; Sharon L Nichols; Paige L Williams; Patricia A Garvie; Cenk Yildirim; Stephen R McCauley; Steven Paul Woods Journal: Child Neuropsychol Date: 2017-08-07 Impact factor: 2.500